-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $151

Benzinga·06/16/2026 15:54:45
Listen to the news
Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $143 to $151.